AAPGAscentage Pharma Group Inc.Signing up patients
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
Ph+ ALL · Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 350 (planned)
- Started
- Aug 31, 2023
- Main results expected
- Dec 31, 2027
- Fully finished
- Jun 30, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Minimal Residual Disease Negative CR Rate
Measured over: Cycle 1 to Cycle 3 (each cycle is 28 days)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06051409 · record last updated 2026-04-30 · checked 2026-11-09 15:47 UTC